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ABBREVIATIONS 
CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; IBI, interburst interval; ICL, 
intracellular loop; MBD, mean burst duration; MSD, membrane-spanning domain; NBD, nucleotide-binding 
domain; Po, open probability; RI, regulatory insertion; RE, regulatory extension; REMD, replica-exchange 
molecular dynamics; RMSF, root mean square fluctuation. 
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ABSTRACT 
People with the genetic disease cystic fibrosis (CF) often carry a deletion mutation ΔF508 on the gene encoding 
the cystic fibrosis transmembrane conductance regulator (CFTR) Cl
‒
 channel.  This mutation greatly reduces 
the CFTR maturation process and slows the channel opening rate.  Here, we investigate whether residues near 
F508 contribute to these defects in ∆F508-CFTR.  Most deletion mutations, but not alanine substitutions, of 
individual residues from position 503 to 513 impaired CFTR maturation.  Interestingly, only protein processing 
of ∆Y512-CFTR, like that of ∆F508-CFTR, was greatly improved by low-temperature culture at 27 °C or small 
molecule corrector C18.  The two mutant Cl
‒
 channels were equally slow to open, suggesting that they may 
share common structural flaws.  Studies on the H3-H4 loop that links residues F508 and Y512 demonstrate that 
G509A/V510G mutations, moving G509 one position backward in the loop, markedly enhanced ∆F508-CFTR 
maturation and opening rate, while promoting protein stability and persistence of the H3 helix in ∆F508 NBD1.  
Moreover, V510A/S511A mutations noticeably increased ∆Y512-CFTR maturation at 27 °C and its opening 
rate.  Thus, loop abnormalities may contribute to ∆F508- and ∆Y512-CFTR defects.  Importantly, correcting 
defects from G509 displacement in ∆F508-CFTR may offer a new avenue for drug discovery and CF treatments. 
 
 
 
 
 
 
Keywords: cystic fibrosis transmembrane conductance regulator (CFTR), ΔF508 mutation, chloride channel, 
low temperature and corrector C18. 
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INTRODUCTION 
The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl
−
 channel on the apical membrane of 
epithelial cells (1, 2).  CFTR is comprised of two membrane-spanning domains (MSDs) that form a 
transmembrane ion pathway, two nucleotide-binding domains (NBDs) that chelate and hydrolyze ATP to drive 
channel opening and closing, termed channel gating, and a regulatory domain that serves as a platform for 
PKA-dependent phosphorylation to activate the channel (3).  Mutations in CFTR disrupt channel function, 
causing the multi-organ disease cystic fibrosis (CF) (1, 2).  Currently, about 90% of people with CF carry the 
ΔF508 mutation, which deletes a phenylalanine residue at position 508 in NBD1 of CFTR (Fig. 1A and S1A).  
This mutation markedly diminishes CFTR function in epithelial cells by two major mechanisms.  First, the 
ΔF508 mutation greatly reduces CFTR expression in the cell membrane due to impaired protein delivery from 
the endoplasmic reticulum (ER) to Golgi apparatus, known as the processing defect (4), and also due to 
accelerated ubiquitin-dependent lysosomal degradation that quickly removes any mutant proteins that reach the 
cell membrane (5).  Second, the ΔF508 mutation slows the channel opening rate of CFTR to decrease channel 
activity to about only 1/4 of that in wild-type CFTR, known as the gating defect (6-9).  The mutation also delays 
and desensitizes CFTR activation by PKA-dependent phosphorylation (10-12).  These findings reveal multiple 
functional deficits in ΔF508-CFTR.  Yet how a single residue deletion elicits such an array of abnormalities in 
CFTR function is not fully understood. 
 
The ΔF508 mutation may cause dysfunction of CFTR due to loss of the backbone function (13, 14) and 
side-chain interactions of the F508 residue (13-16).  Consistent with this scenario, protein misfolding (14, 15, 
17, 18) and aberrant domain-domain interactions between NBD1 and other regions, such as intracellular loop 4 
(ICL4) (14, 16, 19), ICL3 (19) and NBD2 (15), have been documented in ΔF508-CFTR.  Recently solved cryo-
EM structures of wild-type CFTR also reveal intensive interactions of ICL4 with F508 and nearby residues in 
NBD1 (20-22).  In addition, impaired domain-domain interactions might accelerate ΔF508-CFTR degradation 
by the peripheral protein quality control mechanism (5), decrease channel thermostability (23, 24) and reduce 
open probability (Po) (14, 16).  Correcting individual structural defects (23, 25) seems to be a promising strategy 
to restore ΔF508-CFTR function.  However, it is unclear whether loss of function of the F508 residue could 
account for all abnormalities in ΔF508-CFTR. 
 
NBD1 crystal structures of human wild-type and ΔF508-CFTR are similar, except for the loop that 
connects H3 and H4 helices (H3-H4 loop) (Fig. 1A) (18, 26).  Flexibility of the H3-H4 loop in the NBD1 crystal 
structure (26) or synthetic peptides (27) may be enhanced in ΔF508-CFTR.  Moreover, the orientation of loop 
residues 509-511 is also changed in ΔF508 NBD1 (18, 26).  Alterations around this loop, such as the ∆I507 
A loop abnormality in ∆F508-CFTR 
5 
 
mutation (28-30) or mutations of the Y512 residue (31), all impair CFTR processing.  Moreover, structural 
differences between crystal structures of wild-type and ΔF508 NBD1 (18) might be underestimated because 
solubilizing mutations in these constructs partially correct ΔF508-CFTR processing and gating defects (32).  
The structure of ΔF508 NBD1 in the previous study (18) is found different from the recent one (33) that 
contains no solubilizing mutations and removes protein segments of the regulatory insertion (RI) and extension 
(RE).  Therefore, we hypothesized that the ΔF508 mutation might cause structural abnormalities of the H3-H4 
loop, as well as neighboring residues.  Such alterations might contribute to functional defects of ΔF508-CFTR. 
 
We tested this hypothesis by deleting residues near F508 and then examining their effects on CFTR 
processing.  After discovering that the ΔY512 mutation behaved like ΔF508, we further tested whether 
abnormalities of the H3-H4 loop might be a mechanism that initiates both CFTR processing and gating defects. 
 
 
MATERIALS AND METHODS 
CFTR plasmid construction 
Wild-type human CFTR in the pcDNA3.1 expression vector was a generous gift from MJ Welsh, University of 
Iowa.  Various CFTR mutations were created using Stratagene QuickChange II site-directed mutagenesis kit 
(Agilent Technologies, CA) and verified by DNA sequencing. 
 
CFTR expression and small molecule treatments 
Wild-type or mutant CFTRs were transiently expressed in HeLa cells by plasmid transfection.  4 µg plasmid 
and 8 µl Lipofectamine 2000 (Invitrogen) were mixed in Opti-MEM I reduced serum medium (Invitrogen) and 
incubated with cells for 8 h at 37 ºC.  Transfected cells were further cultured at 37 or 27 ºC for 40 h before 
harvest of proteins.  CFTR correctors C4 and C18 (Cystic Fibrosis Foundation Therapeutics), each at 10 µM, 
were added to the culture medium 24 h before protein was harvested.  All small molecules were dissolved and 
frozen in DMSO (x1000, 10 mM) as stocks prior to use. 
 
Immunoblotting 
The Western hybridization method was adopted from a previous study (9).  After washing with ice-cold 
Ca
2+
/Mg
2+
-free PBS solution 3 times, transfected HeLa cells were digested with the lysis buffer containing 150 
mM NaCl, 1% NP40 (Thermo Fisher Scientific, Waltham, MA), 1 mM EDTA, 50 mM Tris (pH 7.4), 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF) and mixed protease inhibitors (cOmplete, Roche) for 1 h at 4 ºC.  Then, 
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cell lysates were centrifuged at ~50,000 g (20,000 RPM) by using a Type 50.4 Ti rotor (Beckman Coulter, CA) 
for 20 mins at 4 ºC.  The supernatant was collected and analyzed by the Bradford assay (Bio-Rad Laboratories, 
Hercules, CA) to determine the protein concentration.  Electrophoresis of 60 or 120 µg total protein in each well 
was run at 150 V for 4 h in 6% SDS-PAGE gels using the Mini-Protean Tetra Cell or Protean II Xi Cell (Bio-
Rad Laboratories, Hercules, CA).  The running buffer contained 25 mM Tris, 192 mM glycine and 0.1% SDS. 
 
Separated proteins in the gel were transferred to the PVDF membrane (IPVH00010, Merck Millipore, 
Billerica, MA) at 30 V and 4 ºC overnight, using the Tetra blotting module (Bio-Rad Laboratories, Hercules, 
CA) with the transfer solution containing 25 mM Tris, 192 mM glycine and 20% methanol.  To detect CFTR, 
PVDF membranes in the 0.1% Casein blocking solution were treated with a mixture of anti-CFTR antibodies: 
M3A7 (Millipore), MM13-4 (Millipore, Billerica, MA) and 13-1 (R&D Systems, Minneapolis, MN) (each 
diluted 1:3000) for 2 h at room temperature.  Then, PVDF membranes were sequentially washed 3 times with 
the TBST solution containing 140 mM NaCl, 0.1% Tween 20 and 20 mM Trizma (pH 7.6 with HCl), incubated 
with the goat anti-mouse IgG-HRP antibody (AP308P, Millipore, Billerica, MA) (1:3000 dilution) in the 0.1% 
Casein blocking solution for 1 h at room temperature and then washed again 3 times with the TBST solution.  
WesternBright ECL HRP substrate (Advansta, Menlo Park, CA) was used to illuminate CFTR.  Images were 
captured using the ChemiDoc XRS system (Bio-Rad Laboratories, Hercules, CA) and analyzed with the 
software Image J (NIH).  To calculate the Band C %, the background intensity was subtracted from the 
measured values. 
 
Electrophysiology 
CFTR currents in excised inside-out membrane patches were recorded using Axopatch 200B patch-clamp 
amplifiers and analyzed with pCLAMP software (both from Molecular Devices, Union City, CA), as described 
previously (34).  The pipette (extracellular) solution contained (mM): 140 N-methyl-D-glucamine (NMDG), 
140 aspartic acid, 5 CaCl2, 2 MgSO4 and 10 TES, pH 7.3 with Tris ([Cl
–
], 10 mM).  The control bath 
(intracellular) solution contained (mM): 140 NMDG, 3 MgCl2, 1 CsEGTA, 5 Trizma base and 5 Bis-Tris, pH 
7.3 with HCl, ([Cl
–
], 147 mM; free [Ca
2+
], <10
-8
 M) at room temperature. 
 
The channel activity of CFTR in excised inside-out membrane patches was activated and maintained 
by adding PKA (75 nM) and ATP (1 mM) to the bath solution in the recording chamber (Brook Industries, IL, 
USA).  Membrane voltage was clamped at –50 mV.  For data analysis and storage, CFTR currents were filtered 
with an 8-pole Bessel filter (model 900; Frequency Devices, Inc., Ottawa, IL) at a corner frequency (fc) of 500 
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Hz and acquired using a Digidata 1440 interface (Molecular Devices) and pCLAMP software at the sampling 
rate of 10 kHz.   
 
For analyzing the patch-clamp data, the number of active channels (N) in a membrane patch was 
determined by the maximum number of recorded channels that opened simultaneously at any one time during 
the entire experiment.  For open probability (Po) and burst analysis, event lists of open- and closed-times were 
created using pCLAMP software with a half-amplitude crossing criterion.  Transitions ≤ 1 ms were excluded 
from event lists (eight-pole Bessel filter rise time (T10-90) ~0.73 ms at fc = 500 Hz). 
 
To measure mean burst duration (MBD), interburst interval (IBI) and Po within a burst (Po-burst), burst 
analysis was performed using recordings from membrane patches that contained 1-4 active channels.  The 
delimiter time (tc) that separates interburst closures from intraburst closures was determined from the point of 
intersection between the two exponential curves fitting fast and slow populations of channel closures in the 
closed-time histogram, as described previously (35).  Event lists and tc values were used to derive MBD and Po-
burst with pCLAMP software.  To obtain burst durations, opening bursts formed by only one active channel were 
measured.  Finally, IBI was calculated using the equation: 
IBIMBD
PMBD
  P burst-oo


  
 
To obtain N accurately, the time required to observe an event where all active channels open 
simultaneously was estimated by the equation: No )/N)/(Pτ(3 o  (36), in which the open time o could be 
estimated by MBD.  For wild-type CFTR with Po = 0.39 and MBD = 401 ms (Fig. 4C, D), it requires ~13 s for 
observing all 4 channels opening at the same time and ~27 s for 5 channels.  Moreover, for ΔF508/AG 
(G509A/V510G)-CFTR with Po = 0.21 and MBD = 351 ms (Fig. 6C, D), it requires ~2.3 mins for N = 4 and 
~8.6 mins for N = 5.  Thus, we recorded CFTR currents in the presence of ATP (1 mM) and PKA (75 nM) for 
6-30 mins for most experiments.  To maintain channel activity, we replaced the bath solution with fresh ATP 
and PKA after recording for 15 mins.  However, N would be underestimated for mutant CFTR with large gating 
anomalies such as ΔF508- and ΔY512-CFTR.  Therefore, reported Po of these two CFTR mutants could be 
considered as maximum Po and their IBI as minimal IBI.   
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For the purpose of illustration, recordings were further digitized at 1 kHz, in which current tracings of 
10 s could clearly demonstrate the gating kinetics of CFTR with reduced data points, noise and some very brief 
current transitions (e.g., those < 1 ms). 
   
Molecular dynamics simulation 
Simulations were performed for ΔF508-G509A/V510G human ΔRI, ΔRE-NBD1, comprising residues 387-646 
(excluding a deletion of residues 405-436) with no additional solubilizing mutations (PDB entries 2PZF, 2.0 Å 
resolution).  This structure was solved by introducing G509A and V510G mutations into the crystal structure of 
ΔF508 NBD1 (PDB: 2PZF) with conformational optimization of neighboring residues within a distance of 5 Å 
using software Discovery Studio 2018 (37).  To incorporate ATP and Mg
2+
 into the structure, the parameters for 
ATP were obtained from the OPLS/AA force field as implemented in Schrodinger (Schrodinger Maestro, 9.0; 
Schrodinger: NY, 2009) while those for Mg
2+
 are included in the GROMACS implementation of this force 
field.  Similar trajectories obtained for wild-type and F508-NBD1 were adopt from the previous study (38).   
 
Replica-exchange molecular dynamics (REMD) simulation was performed using the GROMACS 
package as described previously (38).  In brief, the construct was simulated three times each time starting from 
a different random seed.  The simulation consisted of 32 replicas covering a temperature range of 300 °K (26.85 
°C) to 349.38 °K (76.23 °C) with each replica running for 10 ns.  Thus, the construct was simulated for a total 
of 960 ns (32 replicas x 10 ns x 3 times).    
 
All analyses were performed on the lowest temperature (ground state) replicas.  The dynamic 
behavior of the protein was evaluated by calculating the root mean square fluctuation (RMSF) profile for each 
trajectory.  Prior to RMSF calculation, the entire trajectory was superposed on the starting structure using all 
backbone atoms.  The dynamics of a residue was defined to be significantly different between two constructs 
(e.g., between F508 and F508/AG NBD1) when RMSF values of the residue were consistently higher or 
lower in one construct than those in the other construct across all three simulation repeats.  To predict and 
compare the secondary structure propensity of a polypeptide segment across the different constructs, a 
comparative analysis of the trajectories was performed using the dictionary of secondary structure of proteins 
(DSSP) algorithm. 
 
Reagents, chemicals and resources 
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CFTR correctors are generously provided by the Chemical Compound Distribution Program from Professor 
Robert J. Bridges, Rosalind Franklin University of Medicine and Science, and Cystic Fibrosis Foundation 
Therapeutics.  PKA purified from bovine heart was purchased from Calbiochem/Merck Millipore (Darmstadt, 
Germany).  Stock solutions of ATP were prepared fresh before each experiment.  Except for those indicated in 
the text, all other chemicals were purchased from Sigma (Sigma-Aldrich China, Shanghai, China) in reagent 
grade.  PyMOL software (http://www.pymol.org), a molecular visualization system, was used for preparing all 
structural figures.   
 
Statistics 
Results are expressed as means ± S.E.M. of n observations.  In immunoblotting experiments, n represents the 
number of immunoblots and in electrophysiological experiments, n represents the number of individual 
membrane patches obtained from different cells.  One-way ANOVA was used to analyze sets of data.  
Differences were considered statistically significant when P<0.05. 
 
 
RESULTS 
The F508 residue is located at the end of the H3 helix in NBD1 of human CFTR and connects the H4 helix via a 
flexible loop structure (H3-H4 loop) (Fig. 1A, S1A) (18, 21, 26).  Although deletion of this residue (ΔF508) 
severely impairs CFTR function (4), it shows small impacts on the crystal structure of wild-type NBD1, except 
residues 509-511 of the H3-H4 loop (Fig. 1A) (18, 26, 33).  Interestingly, the NMR spectroscopy study (39) 
demonstrates that phosphorylation-induced conformational changes in wild-type and ΔF508 NBD1 are different 
and that the differences extend beyond the immediate neighborhood of F508.  These findings may suggest that 
if residues match at the level of the crystal structure, it does not necessarily indicate that they also match when 
protein flexibility is introduced.  Therefore, differences in conformation and function of wild-type and ΔF508 
NBD1 may exist in vivo, contributing to ΔF508-CFTR dysfunction (e.g., the protein processing defect (4)).  To 
test this hypothesis, we first asked whether residues near F508 play an important role in CFTR processing.  
 
Effects of residue deletions or substitutions near F508 on CFTR processing 
We began by individually deleting residues within positions 491 to 525 (Fig. 1A) and examining protein 
expression of these CFTR mutants (Fig. 1B, C).  Our data demonstrate that ΔV510- and ΔS511-CFTR 
expressed relatively abundant protein in the Band C form (Band C % = 
C
B+ C
 %, Fig. 1B, C), which may contain 
fully glycosylated CFTR present in the Golgi network and cell membrane as described previously (28).  By 
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contrast, all other mutants including ΔF508-CFTR displayed proteins mostly in the Band B form (Fig. 1B, C), 
representing core glycosylated CFTR in the ER membrane (28).  These data indicate that except for ΔV510 and 
ΔS511, residue deletions near F508 greatly impaired CFTR processing. 
 
From a structural standpoint, removing a residue from a polypeptide chain may lead to two major 
alterations: shortening the peptide chain and removing side-chain interactions of the residue (13).  Following 
this conceptualization, we used alanine substitutions at each residue from position 503 to 513 (Fig. 2A) to retain 
the length of the peptide chain while disrupting side-chain function of the residue for assessing their effects on 
CFTR processing.  The data showed that Band C expression was profoundly decreased by the N505A mutation 
(Fig. 2A), moderately reduced by D513A, and little diminished by K503A, F508A and Y512A (Fig. 2A).  Of 
note, Band C % of I507A-CFTR was 92.2 ± 0.5% (N = 6), similar to that of wild-type CFTR (P>0.05, one-way 
ANOVA).  Interestingly, substitutions of the N505 residue with 8 other different residues all largely decreased 
Band C % (Fig. 2B).  Thus, these data suggest that side chains of N505 and D513 residues are required for 
normal CFTR processing.   
 
To better understand underlying mechanisms, we sought clues from side-chain interactions of these 
two residues with other regions in CFTR (Fig. 2C, S1B, S2C, S3E).  The human NBD1 structure (Fig. 2C, S2C) 
(18, 21) reveals that the side chain of N505 interacts with the backbone of M498 and the side chain of R560.  
Therefore, to test whether intradomain interactions among these three residues are important for CFTR 
processing, site-directed mutations were made at these sites (Fig. 2D).  We found negligible effects of M498A 
and M498F mutations on Band C % (Fig. 2D).  By contrast, the M498P mutation, which might alter backbone 
conformation, greatly decreased Band C % (Fig. 2D).  Moreover, profound reductions in Band C % were also 
observed in R560A-, R560N- and N505R/R560N-CFTR (Fig. 2D).  These data suggest that precise intradomain 
interactions among these three residues N505, M498 and R560 may be required for normal CFTR processing. 
 
In addition, the side chain of D513, which is located on the surface of NBD1 (Fig. 1A, S3E), weakly 
interacts with residues S511, Y512, R516 and Y563 at long distances (Fig. S1B, S3E) (18, 21) and is far from 
residues in other CFTR domains (Fig. S3E) (21).  Thus, we hypothesized that negative charge at this position 
may contribute to the structural integrity required for protein processing.  The data demonstrate that additional 
mutations of D513 with the negative glutamate (D513E), positive lysine (D513K) and neutral leucine residue 
(D513L) showed little, moderate and large reductions in Band C %, respectively (Fig. 2E).  Band C % of 
D513K- (Fig. 2E) and D513A-CFTR (Fig. 2A) were similar, whereas both were smaller than that of D513E-
CFTR (Fig. 2E; P<0.05, one-way ANOVA), consistent with our hypothesis.   
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Taken together, these data suggest that normal CFTR processing requires integrity of all tested residues 
near F508 (Fig. 1) and proper side-chain interactions from D513 and N505 residues (Fig. 2).  For those residues 
whose deletion, but not alanine substitution, strongly diminished CFTR processing (Figs. 1C, 2A), loss of 
backbone function at these positions might be a dominant factor contributing to the CFTR processing defect. 
 
∆Y512-CFTR processing is enhanced by low temperature and CFTR correctors 
Although our study identified deletion mutants near F508 affecting CFTR processing, it is unclear whether they 
have a similar mechanism of dysfunction as ΔF508-CFTR.  We reasoned that if a deletion mutation impairs 
CFTR function by the mechanism similar to that of ΔF508, protein expression of this mutant may be enhanced 
by treatments well-known to rescue ΔF508-CFTR processing (Fig. 3), such as the low-temperature culture at 27 
°C (40) and CFTR correctors C4 (compound 4a) (41) and C18 (25, 29). 
 
Figure 3A demonstrates that after transient expression in HeLa cells for 40 h, ΔF508- and ΔY512-
CFTR cultured at 27 ºC displayed Band C % larger than that at 37 ºC (Fig. 3A).  Moreover, the low-temperature 
culture modestly enhanced Band C % of ΔV510- and ΔS511-CFTR, but slightly decreased Band C % of wild-
type CFTR (Fig. 3A) and was without effects on other deletion mutants (Fig. 3A).  Similarly, 24 h incubation 
with corrector C18 at 37 ºC greatly increased Band C % of ΔF508- and ΔY512-CFTR (Fig. 3B) and enhanced 
that of ΔV510- and ΔS511-CFTR (Fig. 3B), compared to that without treatment (blank columns, Fig. 3B).  
These data suggest that ΔY512 and ΔF508 mutations may impair CFTR processing by similar mechanisms, 
which can be rescued with low temperature or corrector C18. 
 
We also noted that DMSO (0.1%) alone at 37 ºC significantly enhanced Band C % of ΔV510- and 
ΔS511-CFTR about 1.2- and 1.3-fold (blank columns, Fig. 3A, B, P<0.05, one-way ANOVA).  We speculate 
that DMSO enhanced Band C % of ΔV510- and ΔS511-CFTR possibly by acting as a chemical chaperone (42, 
43). 
 
To investigate possible differences between processing defects of the ΔF508- and ΔY512-CFTR, we 
performed combination treatments on these and additional deletion mutants (Fig. 3C, D).  The data demonstrate 
that compared to the vehicle control of 0.1% DMSO at 37 ºC, low temperature or the combination of low 
temperature and corrector C18 showed no apparent increases in Band C % of ΔI506-, ΔG509-, ΔV510-, ΔS511- 
and ΔD513-CFTR (grey and green columns, Fig. 3C).  Since the individual treatment of low temperature or 
corrector C18 at 37 ºC enhanced Band C % of ΔV510- and ΔS511-CFTR (Fig. 3A, B), these data suggest that 
DMSO, low temperature and corrector C18 might have enhanced protein processing of these two mutants by 
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similar mechanisms (Fig. 3A, C), whereas corrector C18 exerted additional effects on these two mutants at 37 
ºC (Fig. 3B, C).   
 
Conversely, low temperature and corrector C18 either alone or together enhanced Band C % of ΔF508- 
and ΔY512-CFTR (Fig. 3C).  By close inspection, we found that the combination treatment promoted an 
additive increase in Band C % of ΔF508-CFTR, compared to individual treatments (Fig. 3C).  However, the 
combination treatment only caused a small synergistic enhancement in Band C % of ΔY512-CFTR (Fig. 3C).  It 
is also important to highlight that Band C % of ΔY512-CFTR was higher than that of ΔF508-CFTR at 37 and 
27 ºC with or without 0.1% DMSO in the culture medium (Fig. 1C, 3A, 3C, 3D, P<0.05, one-way ANOVA).  
Thus, these findings suggest that subtle differences exist between ΔF508- and ΔY512-CFTR in response to low 
temperature and corrector C18.  
 
Recent studies indicate that the F508 residue mediates NBD1-MSDs interactions (Fig. S2F) (20, 21), 
which are disrupted by the ΔF508 mutation (14, 16, 19) but restored by corrector C18 in ΔF508-CFTR (25).  
However, the F508 residue is unchanged in ΔY512-CFTR and the Y512 residue mostly participates in 
intradomain interactions (Fig. S1C, S3D) (21).  Therefore, it is possible that corrector C18 may rescue ΔY512-
CFTR processing by another mechanism related to low temperature-mediated correction. 
 
To further investigate differences in the processing defect between ΔF508- and ΔY512-CFTR, we 
tested these two mutants with CFTR correctors C4 and C18 together at 27 ºC (Fig. 3D).  Our data demonstrate 
that at 27 ºC, correctors C4 and C18 caused additive increases in Band C % of both mutants (Fig. 3D).  
However, corrector C18 exhibited stronger effects than corrector C4 in ΔF508-CFTR (green and black columns, 
Fig. 3D, P<0.05, one-way ANOVA), whereas correctors C4 and C18 alone caused similar stimulations of Band 
C % for ΔY512-CFTR (Fig. 3D).  Different responses to correctors C4 and C18 between ΔF508- and ΔY512-
CFTR (Fig. 3D) suggest that the processing defect of these two mutants may share common mechanisms, 
although to varying degrees. 
 
We next asked whether channel gating of ΔY512-CFTR may display defects similar to those of 
ΔF508-CFTR (6-8). 
 
∆Y512-CFTR gating exhibits low Po and prolonged IBI 
We studied the single-channel activity of 4 deletion mutants: ΔF508-, ΔV510-, ΔS511- and ΔY512-CFTR (Fig. 
4A) that had sufficient protein expression in the cell membrane at 37 or 27 ºC for patch-clamp experiments 
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(Figs. 1B and 3A).  As described in the Methods, we made prolonged, uninterrupted recordings at room 
temperature, where ΔF508-CFTR channel activity is stable (e.g., 44), to accurately determine channel number 
and acquire sufficient transitions to quantify channel gating.  The single-channel current amplitude (i) of these 4 
deletion mutants were similar to that of wild-type CFTR (Fig. 4B).  However, the open probability (Po) (Fig. 4C) 
and mean burst duration (MBD) (Fig. 4D) of ΔV510-CFTR were moderately lower than those of wild-type 
CFTR.  Importantly, the Po of both ΔF508- and ΔY512-CFTR were greatly decreased (Fig. 4C) due to profound 
prolongations of the interburst interval (IBI) (Fig. 4E).  The data showed that deletions in the H3-H4 loop that 
links the F508 and Y512 residues (Fig. 1A, S1A) may alter CFTR gating.  These data also revealed that ΔF508 
and ΔY512 mutations caused similar gating defects of CFTR. 
 
The similarity of CFTR processing and gating defects between ΔF508- and ΔY512-CFTR (Fig. 3 and 4) 
suggests that the H3-H4 loop might be dysfunctional in these two mutants.  In support of this idea, only those 
CFTR mutants with deletions in the loop, including ΔV510-, ΔS511- and ΔY512-CFTR except for ΔG509-
CFTR, showed improvement in protein processing by low-temperature culture or corrector C18 (Fig. 3A and B).  
Previous studies (18, 26) also demonstrate that the orientation of residues 509-511 in ΔF508 NBD1 is 
dramatically different from that of wild-type NBD1.  Thus, it is possible that abnormality of the H3-H4 loop 
may offer a common defect to both ΔF508- and ΔY512-CFTR, although ΔF508 and ΔY512 mutations may 
impair loop structure and function differently.  
 
Deletion of a residue in the H3-H4 loop alone may not play a major role because removing either the 
V510 or S511 residue only moderately reduced CFTR processing (Fig. 1C) and was without effects on IBI (Fig. 
4E).  The data suggest that additional defects from loop residues may impair function of ΔF508- and ΔY512-
CFTR.  To test this hypothesis, we replaced loop residues G509, V510 and S511 in ΔF508- or ΔY512-CFTR 
with alanine or glycine to alter properties of these loop residues (Fig. 5A, B).  Notably, here we assume that 
ΔF508- and ΔY512-CFTR defects are associated with conformational changes of amino acid residues in the 
loop, regardless of other factors such as the effect of the mRNA sequence on protein processing (45). 
 
Displacement of G509 in ∆F508-CFTR and the missing side chain of Y512 in ∆Y512-CFTR caused the 
severe processing defect 
The amino acid sequence of the H3-H4 loop of ∆F508-CFTR could be considered the same as that of ΔV510-
CFTR with two additional mutations F508G and G509V.  Here we assume: ΔF508-CFTR = ΔV510-
F508G/G509V-CFTR.  In other words, we propose that the ΔF508-CFTR processing defect is generated from 
three structural alterations: ΔV510, F508G and G509V.  Therefore, the huge difference in Band C % of ΔV510-
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CFTR ~ 67% and ΔF508-CFTR ~ 4% (Fig. 1C) may be resulted from mutations F508G and G509V in ΔV510-
CFTR.  Furthermore, four structural changes in the residue by these two mutations were noted: (1) F508G 
removes the side chain of F508 and (2) inserts the special residue glycine; (3) G509V introduces the side chain 
of valine while (4) replacing the specific side chain (hydrogen) of glycine.  Thus, we hypothesized that these 
four structural changes may lead to a ~ 63% reduction in Band C % of ΔF508-CFTR. 
 
To test these four mechanisms, we used the mutation G509A that removes special properties of the 
glycine residue, such as the high conformational flexibility and helix breaker, at F508G (mechanism 2, lane 1, 
Fig. 5A) and V510A that eliminates interactions from valine’s side chain (mechanism 3, lane 2, Fig. 5A).  The 
data indicate that G509A, V510A or the double mutation (lane 3, Fig. 5A) showed no apparent improvements in 
Band C % of ΔF508-CFTR, arguing against mechanism 2 and 3.  To test mechanism 1, the F508 residue was 
introduced back to the normal position in ΔV510-F508G/G509V-CFTR to form ΔV510-G509V-CFTR, whose 
amino acid sequence is identical to that of ΔG509-CFTR.  As ΔG509-CFTR exhibited a severe processing 
defect (Fig. 1B, C), mechanism 1 may not be supported by our data.   
 
Therefore, we further examined mechanism 4 by introducing glycine back to the normal position (lane 
#4, Fig. 5A, the ΔF508-G509A/V510G mutation) and found that it markedly enhanced CFTR Band C % to 
about 57%, close to 67% in ΔV510-CFTR (Fig. 1C).  These data suggest that moving the G509 residue back to 
its normal position in ΔF508-CFTR corrects a major part of the processing defect.  We speculate that the rescue 
effect of G509A/V510G mutations is associated with benefits from alterations of loop properties or with 
alleviation of structural flaws brought about by the ΔF508 mutation. 
 
Considering the marked difference in Band C % between ΔF508-G509A/V510A-CFTR (lane #3, Fig. 
5A) and ΔF508-G509A/V510G (ΔF508/AG)-CFTR (lane #4, Fig. 5A), moving the glycine residue backward to 
the V510 position (V510G) in ΔF508-CFTR may play a critical role in improving protein expression.  Two 
possible effects may exist: (1) the glycine residue increases flexibility of the local loop structure or (2) it 
restores formation of the normal H3 helix due to its specific function as the helix breaker.  To test the first 
hypothesis, the loop flexibility was further increased by re-introducing G509 back to position 508 (lane #5, Fig. 
5A, the ΔF508-V510G mutation), which actually decreased Band C %, compared to that of ΔF508/AG-CFTR 
(lane #4, Fig. 5A, P<0.05, one-way ANOVA).  These data suggest that glycine at position 508 in ΔF508-CFTR 
may disrupt protein processing.  Moreover, adding another glycine at position 510 (S511G, lane #6, Fig. 5A) 
further decreased Band C %, compared to that at lanes #4 or #5 (P<0.05, one-way ANOVA).  By contrast, 
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adding V510G or V510G/S511G mutations to wild-type CFTR was without effects on Band C % (lanes #7-8, 
Fig. 5A). 
 
These data suggest that increasing loop flexibility by glycine substitutions is not beneficial for ΔF508-
CFTR processing, but also not harmful for wild-type CFTR expression.  Therefore, restoring G509 position in 
the H3-H4 loop, but not increasing flexibility, may account for the enhanced Band C % of ΔF508/AG-CFTR.  
Furthermore, we speculate that the proper length or persistence of the H3 helix would be required for correcting 
the processing defect of ΔF508-CFTR. 
 
On the other hand, the amino acid sequence of the H3-H4 loop of ΔY512-CFTR is the same as that of 
ΔV510-S511V/Y512S-CFTR.  Therefore, the difference in Band C % of ΔY512- and ΔV510-CFTR (Fig. 1C) 
could result from alterations in side-chain interactions of S511 and Y512 residues.  With alanine substitutions to 
remove side-chain interactions of the replaced residue, our analysis showed that V510A, S511A, V510A/S511A 
and additional G509A/V510A mutations in ΔY512-CFTR did not promote Band C % (lanes #1-4, Fig. 5B).   
 
Conversely, restoration of Y512 back to its normal position creates ΔV510-S511V-CFTR, the same as 
ΔS511-CFTR, which showed protein processing similar to that of ΔV510-CFTR (Fig. 1B, C).  Because the 
Band C % of Y512A-CFTR was relatively good (Fig. 2A), these data suggest that the side chain of Y512 is 
important for CFTR processing only when the loop is shortened by deletion of a residue.  As the phenyl ring of 
Y512 weakly interacts with the side chain of I507 in the H3 helix and E514 and Y515 in the H4 helix (Fig. S1C, 
S3D) (21), we speculate that these side-chain interactions may be important for maintaining the structural 
integrity of NBD1 while the loop is shortened.  
 
Since low temperature and corrector C18 enhanced CFTR processing only for some deletion mutants 
in the H3-H4 loop (Fig. 3A, B), we next asked whether loop mutations alter their effects on ΔF508- and ΔY512-
CFTR processing. 
 
Loop mutations alter the rescue effect of low temperature and corrector C18 on ∆F508- and ∆Y512-
CFTR processing 
To test this hypothesis, we examined the effects of low temperature, corrector C18 or the combination treatment 
on Band C % of ΔF508/AG-CFTR and ΔY512-V510A/S511A (ΔY512/2A)-CFTR (Fig. 5C).  We found that 
low temperature and corrector C18 additively enhanced Band C % of ΔF508/AG-CFTR (Fig. 5C), similar to 
that in ΔF508-CFTR (Fig. 3C).  Because of a greatly improved Band C % of ΔF508/AG-CFTR (Fig. 5A), the 
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enhancement (Fig. 5C) or fold increase (Fig. 5D) in Band C % of ΔF508/AG-CFTR by two different rescue 
methods was much lower than that of ΔF508-CFTR (P<0.05, Fig. 3C, 5D).  Of note, the combination treatment 
enhanced Band C % of ΔF508/AG-CFTR to about 91% (Fig. 5C), close to that of wild-type CFTR (~ 96%) (Fig. 
5A).  These data suggest that G509A/V510G mutations together with low temperature and corrector C18 
rescued most processing defects of ΔF508-CFTR. 
 
Like ΔY512-CFTR, ΔY512/2A-CFTR also showed a large increase in Band C % with corrector C18 
(Fig. 5C).  The fold increases in Band C % by corrector C18 in these two mutants were similar (black columns, 
Fig. 5D).  However, low temperature strikingly promoted Band C % of ΔY512/2A-CFTR (Fig. 5C) and the fold 
increase in Band C % (Fig. 5D) to about 69% and 9.0-fold, respectively, larger than about 50% and 4.4-fold in 
ΔY512-CFTR (P<0.05, Fig. 3C, 5D).  Moreover, corrector C18 at 27 ºC only showed a small synergistic 
increase in Band C % of ΔY512/2A-CFTR (Fig. 5C), similar to that of ΔY512-CFTR (Fig. 3C).  Therefore, 
these data suggest that removing side chains of V510 and S511 from ΔY512-CFTR magnified the low 
temperature-mediated correction of the protein processing defect.  All data support our hypothesis, suggesting 
that residue properties of the H3-H4 loop are associated with the rescue effect of low temperature and corrector 
C18 on ΔF508- and ΔY512-CFTR processing.   
 
Next, we asked whether the gating defect of ΔF508- and ΔY512-CFTR could be alleviated by loop 
mutations. 
 
IBI prolongation of ΔF508- and ΔY512-CFTR is attenuated by loop mutations 
When compared to wild-type CFTR, ΔF508/AG- and ΔY512/2A-CFTR showed no alterations in the single-
channel current amplitude (i) and MBD (Fig. 6A, B, D).  However, the Po of ΔF508/AG- and ΔY512/2A-CFTR 
were moderately decreased (Fig. 6C) due to an approximately 2-fold prolongation of IBI (Fig. 6E).  Importantly, 
the IBI of ΔF508/AG- and ΔY512/2A-CFTR (Fig. 6E) were shorter than those of ΔF508- and ΔY512-CFTR, 
respectively (P<0.05 for both mutants, Fig. 4E).  As a result, the channel activity (Fig. 6A) and Po (Fig. 6C) of 
ΔF508/AG- and ΔY512/2A-CFTR appeared greater than those of ΔF508- and ΔY512-CFTR, respectively (Fig. 
4A, C; P<0.05 for Po for both mutants).  Because G509A/V510G mutations strikingly rescued ΔF508-CFTR 
processing and gating, the data suggest that they are revertant mutations similar to those described previously 
(e.g., 46-51).  These data further suggest that displacement of the G509 residue in the H3-H4 loop may be a 
pivotal defect that underlies functional abnormalities of ΔF508-CFTR. 
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We next asked whether the rescue effects of G509A/V510G mutations may be associated with 
alterations in the structure and dynamics of NBD1.  The crystal structure of ΔF508/AG NBD1 was modeled 
from ΔF508 NBD1 (PDB: 2PZF) and then subjected to replica-exchange molecular dynamics (REMD) 
simulation (Fig. 7A) and the secondary structure analysis (Fig. 7B, Table 1). 
 
G509A/V510G mutations enhance protein stability of ΔF508 NBD1 and persistence of the H3 helix  
Figure 7A presents the profiles of the root mean square fluctuation (RMSF) obtained from three simulations of 
ΔF508/AG NBD1, compared to similar profiles obtained for wild-type (modeled after PDB: 2PZE) and ΔF508 
NBD1 as previously described (38).  The data indicate that the dynamics of residues, measured by the RMSF 
value, varied modestly among the three NBD1 constructs (Fig. 7A).  Interestingly, two regions corresponding to 
residues 502-505 and 510-511 (vertical grey shading, Fig. 7A) showed consistent differences in the RMSF 
values across the three simulations with the order wild-type < ΔF508 < ΔF508/AG and wild-type < ΔF508/AG 
< ΔF508, respectively.  Further analysis indicated that 25% of the residues (57 residues) in ΔF508/AG NBD1 
displayed lower RMSF values than those in ΔF508 NBD1, whereas only 3% of the residues (6 residues) showed 
higher values.  These data suggest that G509A/V510G mutations reduce the dynamics of specific residues in 
ΔF508 NBD1 or in other words, they enhance the structural stability of ΔF508 NBD1.  Moreover, the previous 
study (38) has demonstrated that the protein stability of ΔF508 NBD1 is lower than that of wild-type NBD1.  
Therefore, we speculate that mutations G509A/V510G may rescue the functional defects of ΔF508-CFTR 
partly by stabilizing NBD1 structure. 
 
To investigate the molecular basis for above alterations in protein stability of NBD1, further analysis of 
ΔF508/AG NBD1 revealed apparent increases in residual interactions around regions near residues 509-510.  
First, H-bond formation between residues 511 and 563 (Fig. S3C) occurred in 53% of simulations with 
ΔF508/AG NBD1, but only 36 % in ΔF508 NBD1.  Second, H-bonds between K503 and D537 (Fig. S2A) and 
between R560 and N505 (Fig. 2C and S2C) in ΔF508/AG NBD1 were maintained across 27% and 18% of total 
simulations, respectively, in contrast to 17% and 8% in ΔF508 NBD1. 
 
Since the helix is important for stabilizing the tertiary structure of the protein (52), we next analyzed 
the time evolution (Fig. 7B) and the percentage of time (%) (Table 1) in which residues 491-525 adopt specific 
secondary structures during the simulation of wild-type, ΔF508/AG and ΔF508 NBD1.  Our data demonstrate 
that the helicity of the H4 helix is well maintained in all constructs throughout the simulations (Fig. 7B, Table 
1).  However, the persistence of the H3 helix formed by residues 502-507 was disrupted in ΔF508 NBD1, 
compared to that in wild-type NBD1 (blue color, Fig. 7B).  This is evident by observing that almost all residues 
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making up this helix spent less time in an α-helix secondary structure (Table 1).  In contrast, the persistence of 
the H3 helix in ΔF508/AG NBD1 appeared to be higher than that in ΔF508 NBD1 (Fig. 7B, Table 1).  However, 
Table 1 also indicates that the length of the H3 helix in ΔF508 NBD1 was not increased upon the introduction 
of G509A/V510G mutations since the helicity of residue I507 was seemly reduced in this construct.    
 
The secondary structure of the H3-H4 loop varied greatly among three constructs in residues 509-511 
(Fig. 7B, Table 1).  G509 and V510 in wild-type NBD1 mostly maintained the structure of a bend or a turn 
(Table 1).  For ΔF508/AG NBD1, residues 509-511 spent more time in the bend structure (Table 1).  For ΔF508 
NBD1, only V510 frequently occupied the bend conformation, whereas G509 and S511 resided more often in 
the random coil structure (Table 1).  These data might suggest that maintaining a bend and turn conformation 
for residues 509-511 is associated with structural stability required for normal CFTR function. 
 
Taken together, these data suggest that the revertant mutation G509A/V510G might correct the ΔF508-
CFTR defects partly by altering the NBD1 structure, leading to increased protein stability, persistence of the H3 
helix and maintenance of bends and turns in residues 509-511 in the H3-H4 loop. 
 
 
DISCUSSION 
Table S1 summarizes treatments and results obtained for key CFTR mutations tested in this study.  Our study 
revealed that side chains of N505 and D513 and the backbone of residues from the H3 helix (residues 502-508), 
H3-H4 loop (509-512) and H4 helix (513-524) in CFTR NBD1 (53) are structurally important for normal CFTR 
processing.  We also found that the position of the G509 residue in the polypeptide chain is the major factor that 
distinguishes Band C expression between ∆F508- and ∆V510-CFTR.  Data obtained for loop mutations 
G509A/V510G in ∆F508-CFTR and V510A/S511A in ∆Y512-CFTR suggest that conformational changes of 
residues in the H3-H4 loop and/or persistence of the H3 helix may contribute to the processing and gating 
defects of ∆F508- and ∆Y512-CFTR.  We speculate that these local structural changes near F508 may alter the 
stability of the H3 helix, local peptide folding, surface topology of NBD1 and side-chain interactions. 
 
The role of the backbone and side chain of residues near F508 in CFTR processing 
It has been a question for many years how the most prevalent CF mutation ΔF508 deletes only a single residue 
in CFTR, but causes multiple dysfunctions.  Other CF mutations at NBD1, such as ΔI507, S549I, R560T and 
A561E (28, 50) also severely impair Band C expression of CFTR.  Recent studies suggest that the ΔF508 
mutation may alter NBD1 properties by affecting its folding efficiency (13, 17, 18, 54) and folding kinetics (55, 
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56) with a reduced thermodynamic stability of the native state (57).  The ΔF508 mutation also impairs CFTR 
assembly (58) partly due to abnormal domain-domain interactions (14-16, 18).  CFTR correctors and 
potentiators may rescue ΔF508-CFTR defects by targeting some of these abnormalities (23, 25, 59).  
 
Surprisingly, most single-residue deletions near F508 in this study caused pronounced CFTR 
processing defects that could not be attributed to side-chain removal alone nor could they be rescued by low 
temperature or corrector C18.  As the backbone of F508 plays a role in proper NBD1 folding (13), it is possible 
that abnormal folding may account for the processing defects of these deletion mutants.  Following this idea, 
side chains of residues 503-513 mostly interact with other residues in NBD1, except that F508 and G509 also 
interact with ICL4 (Fig. S2, S3) (21).  Moreover, since the H3-H4 loop makes a turn with residues 508-513 (Fig. 
1A and S1A), deletion of residues in the middle of the loop, such as V510 and S511, may have minimal effect 
on folding since other residues could re-adjust their positions to compensate for the deletion (Fig. S3B, C).  Our 
data support this hypothesis as these deletions only moderately disrupted CFTR processing (Fig. 1B, C).  In 
contrast, deletion of residues at either end of the H3-H4 loop, including F508, G509, Y512 and D513, may 
significantly disrupt folding interactions (Fig. S2F, S3A, D, E) and indeed they strongly disrupted CFTR Band 
C expression (Fig. 1B, C). 
 
We also found that intradomain interactions between residues N505 in the H3 helix, M498 in the Q 
loop and R560 in the H4 helix, contribute to structural integrity required for normal CFTR expression (Fig. 2, 
S2C).  REMD simulation analysis in this study also showed that H-bond interactions between N505 and R560 
in ΔF508/AG NBD1 occurred more frequently than that in ΔF508 NBD1.  Recent work suggests that M498 and 
R560 structurally locate at the interface between NBD1 and ICL4 by the F508 residue (S2C) (20, 21, 60).  
Moreover, the exposed surface of these two residues is seemly largely extended in ΔF508-CFTR (61).  
Predicted by structure-based virtual screening, several novel small-molecule compounds for promoting ΔF508-
CFTR expression may dock at the site containing M498 and R560 residues (62).  These data suggest that 
interactions from the side chain of N505 may be important for NBD1 stability and could be a target for drug 
therapy. 
 
G509 plays an important role in the processing defect of ∆F508-CFTR 
Our data suggest that G509 shifted one position forward in the ΔF508-CFTR polypeptide chain contributes 
primarily to the processing defect.  Our molecular analysis data (Fig. 7, Table 1) suggest that G509 in ΔF508-
CFTR may destabilize the H3 helix and affect the bend and turn conformation of residues 509-511 in the H3-H4 
loop.  This is consistent with the well-known property of glycine as a helix breaker.  Similarly, F508G-CFTR 
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like ΔF508-CFTR shows very little Band C expression (13, 15, 25).  However, with the F508 residue 
unchanged, the ΔG509, but not G509A mutation profoundly reduced Band C expression of CFTR (Fig. 1C, 2A).  
Moreover, the F508A mutation exerted only small (Fig. 2A) or moderate reductions in Band C % of CFTR (13, 
15, 63).  The moderate Band C protein level of F508A- and G509A-CFTR suggests that when the length of the 
polypeptide chain remains unchanged, removing interdomain interactions from the side chain of F508 or 
disrupting the helix-breaker function of G509 has minor impacts on CFTR processing.  Therefore, in ΔF508-
CFTR, structural constraints generated by deletion of the F508 residue may be a primary cause of the defect, 
and together with G509 displacement greatly impair CFTR processing.   
 
Recent studies (14, 16, 19) demonstrate that functional defects of ΔF508-CFTR are associated with 
abnormal interactions of NBD1 with ICL4 in MSD2, such as interactions between F508 and R1070 (Fig. S1A, 
S2F) (21).  Restoring or enhancing these NBD1-ICL4 contacts have been shown to promote ΔF508-CFTR 
processing (14, 16, 19, 25, 64).  Based on this mechanism, it is possible that the revertant mutation 
G509A/V510G-induced enhancements in the predicted stability of NBD1 and persistence of the H3 helix in 
ΔF508-CFTR (Fig. 7, Table 1) may facilitate NBD1-ICL4 interactions for promoting CFTR processing.     
 
Contributions of the H3-H4 loop to the ΔF508-CFTR processing defect  
Our data suggest that the H3-H4 loop in CFTR may play an important role in structural integrity required for 
normal protein processing and channel gating.  Generally, loop structures form a connector between two rigid 
elements such as helices or β-sheets and works like a flexible hinge allowing for the folding of a peptide chain 
or like an allosteric regulator of domain-domain interactions (65).  CFTR cryo-EM structures (20, 21) show that 
the H3-H4 loop interacts mostly with other intradomain residues in NBD1 (Fig. S2, S3), except for the residues 
F508 and G509 which are positioned close to the R1070 residue (Fig. S2F, S3A).  Although it is unclear 
whether this loop exhibits dynamic and multiple conformations in native CFTR for domain-domain interactions, 
our data suggest that neither removing interactions from each residue’s side chain nor increasing loop flexibility 
by glycine substitutions altered Band C expression of wild-type CFTR (Fig. 2A, 5A).   
 
By contrast, residue deletions in the loop displayed varying impacts on Band C % of CFTR (Fig. 1B, 
C).  Because this loop turns the H3 and H4 helices to face each other for chelating the H5 helix in NBD1 (Fig. 
2C, S1A), these data suggest that the loop-mediated helix-turn-helix structure, possibly affected by deletion-
induced constraints, may be an important factor regulating CFTR processing.  Consistently, our data indicate 
that the bend and turn secondary structures of residues 509-511 seemly occurred more frequently in wild-type 
and ΔF508/AG NBD1 than that in ΔF508 NBD1 (Fig. 7B, Table 1).  Moreover, residues 502-524 covering the 
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H3 helix, loop and H4 helix are highly conserved in CFTR among different species (Fig. S4).  Key residues for 
maintaining normal CFTR processing such as N505, F508, G509, Y512 and D513 are also highly conserved in 
these CFTR orthologues (Fig. S4).  These data may reveal the importance of theses residues in structural 
integrity required for normal CFTR function.   
 
Our data indicate that structural changes of residues in the shortened loop were associated with the low 
temperature-rescued processing defect in ΔF508- and ΔY512-CFTR.  Low temperature may facilitate CFTR 
thermodynamic folding and enhance thermal stability (17, 23, 24, 54, 56, 57, 66-69), suggesting that protein 
stability of NBD1 may be associated with the functional defects of ΔF508-CFTR.  Similarly, the revertant 
mutation G509A/V510G enhanced the predicted protein stability of ΔF508 NBD1 (Fig. 7A).  Previous work 
using REMD simulations (38) demonstrates that the dynamics of some residues in the H3 and H5 helices were 
different between wild-type and ΔF508 NBD1 (Fig. 7A).  Interestingly, several second-site revertant mutations 
that improve ΔF508-CFTR processing are found in the H5 helix, such as G550E, R553M, and R555K (46, 47, 
50, 63, 70).  Some of these mutations also increase both the protein (38) and thermal (57) stability of ΔF508 
NBD1.  Therefore, these data suggest that NBD1 instability may be associated with the ΔF508-CFTR defects.     
 
Our study demonstrates that Band C expression of CFTR was largely reduced by all deletion mutations 
in H3 and H4 (Fig. 1) or by site-directed mutations at N505 and R560 residues in H3 and H5 helices, 
respectively (Fig. 2).  Similarly, trivial Band C expression is observed in the CF mutant R560T- (30, 50, 71) and 
R560S-CFTR (72).  Taken together, our own and previous data highlight the importance of H3, H4 and H5 
helices in achieving normal CFTR processing.  We speculate that loop mutations and other mutations near F508 
may disturb the alignment of these three helices, resulting in abnormal NBD1 folding and stability, which could 
be recognized as a structural defect by quality control mechanisms in the ER (4), targeting CFTR for 
degradation. 
 
Revertant mutations of the loop partially correct the CFTR gating defect 
The gating defect of ∆F508-CFTR is characterized by a slow channel opening rate, which is shown as 
prolonged IBI in CFTR gating kinetics (Fig. 4E) (6-8).  The channel opening rate of ∆F508-CFTR can be 
markedly enhanced by introducing revertant mutations near ATP binding sites (50), by mutations at domain-
domain interfaces between NBD1 and MSD1, MSD2 or NBD2 (14, 16, 19, 73) or by adding potentiators to 
stimulate ATP-dependent CFTR gating (7, 74).  Interestingly, those revertant mutations that correct domain-
domain interactions between NBD1 and other regions in CFTR such as R1070W in ICL4 (14, 73) or that may 
affect ATP function in two NBDs such as G550E (50) all greatly stimulate the channel activity of ΔF508-CFTR, 
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but show little or no effects on CFTR processing (14, 16, 19, 50, 73).  These data may suggest that the 
processing and gating defect of ΔF508-CFTR are generated by different mechanisms (19).   
 
However, in this study loop mutations G509A/V510G greatly enhanced both the Band C expression 
(Fig. 5A) and channel activity of ΔF508-CFTR (Fig. 6A).  Similarly, V510A/S511A mutations greatly enhanced 
the rescue effect of low temperature on protein processing of ΔY512-CFTR (Fig. 5C) and partially corrected its 
gating defect (Fig. 6E).  Our data suggest that deletion of a residue and displacement of the G509 residue in the 
H3-H4 loop form pivotal defects of ΔF508-CFTR, possibly further inducing structural abnormalities that 
separately lead to either the processing or channel gating defect. 
 
In conclusion, this study characterized the role of residues near F508 in CFTR processing.  Our data 
suggest that abnormalities of the H3 helix and the H3-H4 loop may impair CFTR processing and gating, and 
contribute to dysfunction of ΔF508-CFTR.  We also found that low temperature and corrector C18 stimulated 
protein expression of not only ΔF508-CFTR but also some other CFTR deletion mutants that miss a residue in 
the H3-H4 loop.  Therefore, even if drug cocktails of CFTR correctors and potentiators provide a promising 
cure for people with CF (75), our data highlight the possibility that small molecules, which correct defects in the 
H3 helix and H3-H4 loop might rescue both the processing and gating defects of ΔF508-CFTR.   
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Table 1.  Residence of residues 502-524 adopted specific secondary structure conformations calculated from 
three REMD simulations of wild-type, ΔF508/AG and ΔF508 NBD1. 
H3 Helix α-Helix    3-Helix      
Residues WT ΔF/AG ΔF508  WT ΔF/AG ΔF508     
502 60±4 58±2 42±5*  1±0 4±1* 2±1     
503 71±4 64±2
#
 46±5*  6±1 15±1 16±4     
504 85±3 67±2 54±8*  6±1 15±1 16±4     
505 85±3 67±2 54±8*  6±1 13±1 16±4     
506 85±2 56±1* 52±9*  0±0 0±0 0±0     
507 44±6 8±2* 20±8*  0±0 0±0 0±0     
            
H3-H4 Loop Coil    Bend    Turn  
Residues WT ΔF/AG ΔF508  WT ΔF/AG ΔF508  WT ΔF/AG ΔF508 
509 0±0 35±5*
#
 62±3*  56±6 59±4
#
 21±3*  44±6 6±1* 17±5* 
510 2±0 0±0 0±0  98±0 94±1 86±4*  0±0 6±1 14±4* 
511 100±0 23±2*
#
 54±1*  0±0 77±2*
#
 45±1*  0±0 0±0 1±1 
512 100±0 100±0 100±0  0±0 0±0 0±0  0±0 0±0 0±0 
513 100±0 100±0 100±0  0±0 0±0 0±0  0±0 0±0 0±0 
            
H4 Helix α-Helix    3-Helix      
Residues WT ΔF/AG ΔF508  WT ΔF/AG ΔF508     
514 99±0 99±0 95±2  0±0 0±0 0±0     
515 100±0 100±0 98±1  0±0 0±0 0±0     
516 100±0 100±0 98±1  0±0 0±0 0±0     
517 100±0 100±0 100±0  0±0 0±0 0±0     
518 100±0 100±0 100±0  0±0 0±0 0±0     
519 99±0 98±1 98±0  0±0 0±0 0±0     
520 100±0 100±0 100±0  0±0 0±0 0±0     
521 100±0 99±0 100±0  0±0 0±0 0±0     
522 98±0 96±0 97±0  0±0 0±0 0±0     
523 98±0 96±0* 97±0  0±0 0±0 0±0     
524 10±1 9±0*
#
 12±0*  0±0 0±0 0±0     
Data show the percentage of time (%) measured from Figure 7B.  Data are means ± S.E.M. (N=3 for all data) 
for wild-type (WT), ΔF508/AG (ΔF/AG) and ΔF508 NBD1.  *, P<0.05 vs. wild-type NBD1, one-way ANOVA.  
#
, P<0.05, ΔF508/AG vs. ΔF508 NBD1, one-way ANOVA.  For further details, see Figure 7.  
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FIGURE LEGENDS 
Figure 1.  Localized deletions near the F508 residue severely impair CFTR processing.  A) Comparison of 
NBD1 structures between human wild-type CFTR (grey; PDB: 2BBO) and ΔF508-CFTR (green; PDB: 1XMJ).  
Expanded figure on the right displays the aberrant H3-H4 loop (blue) in ΔF508-NBD1 vs. the normal (grey) in 
wild-type NBD1.  Yellow dots indicate positions of residues tested in panel B.  B, C) Immunoblotting image (B) 
and quantitative data (C) show protein expression of wild-type (WT) and mutant CFTR.  Columns in grey 
represent the data of CFTR mutants with deletions outside positions 503-513.  The percentage of Band C 
expression (
C
B+C
%) was calculated by measuring protein band intensity of Band C vs. that of Bands B+C.  Data 
are means + S.E.M. (N = 6-8).  *, P<0.05 vs. wild-type CFTR, one-way ANOVA. 
 
Figure 2.  Side-chain function of N505 and D513 residues is required for normal CFTR processing.  A–E) 
Effects of site-directed mutations on CFTR processing with alanine substitutions at residues from positions 503 
to 515 (A) (N=6-8) and with substitutions of different residues for N505 (B) (N = 6-7), at N505, M498 and 
R560 (C, D) (N = 5-7) or at D513 (E) (N = 6-8).  Data of wild-type (WT) CFTR were adapted from Figure 1C.  
Data are means + S.E.M.  *, P<0.05 vs. wild-type CFTR, one-way ANOVA.  See other details in Figure 1.   
 
Figure 3.  The processing defect of ΔY512-CFTR is rescued by low temperature and CFTR correctors.  A–D) 
Band C % of wild-type (WT) CFTR or indicated mutants incubated at 27 °C (A), treated with the CFTR 
corrector C18 (10 µM) (B), treated with corrector C18 at 27 °C (C) or treated with correctors C18 and C4 (10 
µM) at 27 °C (D).  In (A), the control data were adapted from Figure 1C for each CFTR variant.  The vehicle 
controls of 0.1% DMSO were tested at 37 °C (B, C) or at 27 °C (D).  Data are means + S.E.M. (N = 6-10).  *, 
P<0.05 vs. control, one-way ANOVA.  #, P<0.05 between two sets of the data in ΔF508- or ΔY512-CFTR, 
one-way ANOVA. 
 
Figure 4.  Channel gating of ΔY512-CFTR exhibits prolonged IBI.  A) Representative recordings show the 
single-channel activity of wild-type and mutant CFTR in the presence of ATP (1 mM) and PKA (75 nM).  
Dotted lines indicate the closed state and downward deflections correspond to channel openings.  B–E) The 
single-channel current amplitude (i) (B), open probability (Po) (C), mean burst duration (MBD) (D) and 
interburst interval (IBI) (E) of wild-type and mutant CFTR are shown.  Data are means + S.E.M. (N = 6, except 
ΔF508-CFTR where N = 4).  *, P<0.05 vs. wild-type CFTR, one-way ANOVA.   
 
Figure 5.  Differential effects of H3-H4 loop mutations on the correction of ΔF508- and ΔY512-CFTR 
processing.  A, B) Effects of alanine or glycine substitutions at the H3-H4 loop on Band C % of ΔF508- (A) and 
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ΔY512-CFTR (B).  Wild-type, ΔF508- or ΔY512-CFTR were used as controls (blank columns).  In (A), the 
image of ΔF508-G509A/V510A-CFTR was acquired separately from the other data.  C) Effects of low 
temperature and corrector C18 on Band C % of ΔF508/AG (G509A/V510G)-CFTR and ΔY512/2A 
(V510A/S511A)-CFTR.  Blank columns represent the data of the vehicle control of 0.1% DMSO at 37 °C.  
Notably, a protein band between Band B and C was evidently found in the immunoblot of ΔF508/AG-CFTR in 
the presence of corrector C18, but excluded from the analysis in this and other experiments (e.g., Fig. 3D) due 
to lack of the control.  D) The fold increase in Band C % of ΔF508-, ΔF508/AG-, ΔY512- and ΔY512/2A-
CFTR by low temperature or corrector C18 vs. the control at 37 °C with no treatment (blank bars).  Fold 
increase in Band C % = (Band C %-treatment) / (Band C %-no treatment control at 37 ºC).  Dotted lines indicate the fold 
increase in Band C % = 1 for the control.  All data are means + S.E.M. (N = 6-10); *, P<0.05 vs. the control 
(blank columns), one-way ANOVA; #, P<0.05 between two groups, one-way ANOVA. 
 
Figure 6.  The IBI of ΔF508/AG- and ΔY512/2A-CFTR are only mildly prolonged.  A) Representative 
recordings show the single-channel activity of ΔF508/AG- and ΔY512/2A-CFTR in the presence of ATP (1 
mM) and PKA (75 nM).  Dotted lines indicate the closed state and downward deflections correspond to channel 
openings.  B–E) The single-channel current amplitude (i), Po, MBD and IBI of two mutants are shown.  Data are 
means + S.E.M. (N = 6 for both mutants).  *, P<0.05 vs. wild-type CFTR, one-way ANOVA.   
 
 
Figure 7.  The revertant mutation G509A/V510G enhances protein stability and persistence of the H3 helix in 
ΔF508 NBD1.  A) Three REMD simulations of wild-type (blue), ΔF508/AG (green) and ΔF508 (red) NBD1 
constructs.  Two vertical grey shadings indicate the RMSF values of residues 502-505 and 510-511, 
respectively.  Data of wild-type and ΔF508 NBD1 were retrieved from the previous publication (38) with 
permission.  B) Representative DSSP plots show persistence of secondary structure elements for residues 491-
525 in wild-type (top), ΔF508/AG (middle) and ΔF508 (bottom) NBD1.   
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A defective flexible loop contributes to the processing and gating defects of the predominant cystic 
fibrosis-causing mutation 
SUPPLEMENTAL DATA 
Table S1.  Summary results of protein expression of key CFTR mutants tested in this study. 
 
Residues K503 E504 N505 I506 I507 F508 G509 V510 S511 Y512 D513 
            
Alanine 
substitution A A A A A A A A A A A 
Expression scale 
37°C 
 
+++++ 
 
+++++ 
 
+ 
 
+++++ 
 
+++++ 
 
+++++ 
 
+++++ 
 
+++++ 
 
+++++ 
 
+++++ 
 
+++++ 
            
Deletion 
mutation 
Δ Δ Δ Δ  Δ Δ Δ Δ Δ Δ 
Expression scale 
37°C 
 
+ 
 
+ 
 
+ 
 
+ 
 
 
 
+ 
 
+ 
 
+++++ 
 
+++++ 
 
+ 
 
+ 
27°C + + + +  +++ + +++++ +++++ ++++ + 
37 °C + C18 + + ++ +  +++ + +++++ +++++ +++++ ++ 
27 °C + C18    +  +++++ + +++++ +++++ +++++ ++ 
27 °C + C4      ++++    +++++  
27°C + C4 + C18      +++++    +++++  
            
            
            
Loop residues  F508 G509 V510 S511 Y512 Expression scale *Band C % N 
ΔF508-CFTR  Δ     +  4.8 ± 0.6 6 
+ G509A  Δ A    +  6.4 ± 0.9 11 
+ V510A  Δ  A   ++  12.1 ± 2.9 11 
+ G509A/V510A  Δ A A   +  7.1 ± 0.6 17 
+ V510G  Δ  G   ++++  31.3 ± 2.3 15 
+ V510G/S511G  Δ  G G  +  6.6 ± 0.8 11 
           
+ G509A/V510G  Δ A G   +++++  56.8 ± 2.3 15 
37 °C + C18  Δ A G   +++++  75.8 ± 1.2 6 
27 °C  Δ A G   +++++  67.2 ± 2.7 6 
27 °C + C18  Δ A G   +++++  90.8 ± 1.6 6 
           
           
Loop residues  F508 G509 V510 S511 Y512 Expression scale *Band C % N 
ΔY512-CFTR      Δ +  7.5 ± 0.3 6 
+ V510A    A  Δ +  7.5 ± 0.7 6 
+ S511A     A Δ +  7.2 ± 0.8 6 
           
+ V510A/ S511A    A A Δ +  8.0 ± 0.6 12 
37 °C + C18    A A Δ ++++  33.6 ± 1.0 6 
27 °C    A A Δ +++++  68.7 ± 1.8 6 
27 °C + C18    A A Δ +++++  81.1 ± 1.3 6 
            
 
Note: Expression scale is defined as follows: +, Band C % < 10%; ++, < 20%; +++, < 30%; ++++, < 40%; +++++, 
≧ 40%.  N indicates the number of experiments.  Blank spots indicate no experiment performed.  In most 
experiments, cells were cultured at 37 °C except where shown at 27 °C.   
*, means ± S.E.M. of Band C % are shown.   
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SUPPLEMENTAL FIGURE LEGENDS 
Figure S1.  Positions of key secondary structures and residues in NBD1 tested in this study.  A) Positions of the 
H3, H4 and H5 helices, F508 residue (red) and H3-H4 loop (orange) are displayed in the cryo-EM structure of 
human wild-type CFTR (PDB: 5UAK) with MSD1 in blue color, NBD1 in grey and MSD2 and NBD2 in green.  
B, C) Residues that interact with side chains of the D513 (B) and Y512 (C) residue are shown in NBD1 of cryo-
EM human wild-type CFTR.   
 
Figure S2.  Side-chain interactions of residues 503-508 in the cryo-EM structure of human wild-type CFTR.  A-
F) Side-chain interactions of K503 (A), E504 (B), N505 (C), I506 (D), I507 (E) and F508 (F) are shown.  Only 
the shortest distance (< 6 Å) is drawn between two residues.  Distance of two atoms is labelled for those polar 
chemical bonds.  For the purpose of illustration, residues 515-516 were omitted from the structures.  See other 
details in Figure S1. 
 
Figure S3.  Side-chain interactions of residues 509-513 in the cryo-EM structure of human wild-type CFTR.  A-
F) Side-chain interactions of G509 (A), V510 (B), S511 (C), Y512 (D) and D513 (E) are shown.  For further 
details, see Figures S1 and S2. 
 
 Figure S4.  Amino acid sequence alignment of CFTR orthologues for residues 501 to 553.  Residues that differ 
from that at the same position in human wild-type CFTR are identified by blue letters and grey background.  
Percentage similarity was calculated using the equation: (number of matched residues) / (total number of CFTR 
orthologues [45]) * 100%.   
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